| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 746.0 | 705.4 | 587.4 |
| Other income | 5.8 | 4.1 | 1.7 |
| Total income | 751.8 | 709.5 | 589.1 |
| Profit before exceptional items & tax | 87.6 | 133.7 | 69.7 |
| Profit before tax | 87.6 | 133.7 | 69.7 |
| Net profit | 65.1 | 99.7 | 51.2 |
| Operating margin | 11.7% | 18.8% | 11.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +27.10% |
|---|---|
| Net profit, quarter on quarter | -34.70% |
| Revenue, year on year | +27.00% |
| Operating profit, year on year | +20.30% |
| Operating profit, quarter on quarter | -36.90% |
BSE results filing, NSE: EPIGRAL. Figures extracted from the filing.
Epigral Ltd: key numbers
- Share price
- ₹874.50
- Market cap
- ₹3,773 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 13.9×Sector 34.1×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 0.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Investor Presentation: Key Takeaways
Q2FY27 revenue ₹752 Cr (+28% YoY) and PAT ₹64 Cr (+26%). EBITDA margin fell to 18% (23% YoY) on raw material costs. Derivatives & Specialty now 57% of revenue. CPVC and ECH capacity due Q3FY27.
Epigral Results Update
Epigral reported Q2 FY27 PAT of ₹64 Cr, up 26% YoY, with revenue at ₹752 Cr. EBITDA margin was 18% despite elevated raw material costs.
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Epigral Legal & Regulatory
Epigral received a Rs.28.11 crore income tax demand for AY 2023-24, including interest. The company considers the demand unmaintainable and is filing an appeal.
- Value
- ₹28.11 Cr
Epigral Board Meeting Date
Epigral schedules a board meeting on November 2, 2026 to approve unaudited Q2 and half-year results ended September 30, 2026. The notice is issued for shareholder information.
Epigral Other Announcement
Epigral Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, regarding security dematerialization for the quarter ended September 30, 2026.